Lexicon Pharmaceuticals Secures $100M Loan Facility from Hercules Capital
Event summary
- Lexicon Pharmaceuticals has secured a $100 million loan facility from Hercules Capital, with an initial $55 million tranche funded at closing.
- The loan carries a floating interest rate of prime plus 3.1%, with a floor of 9.85%, and matures on May 4, 2030.
- The facility includes a second $20 million tranche contingent on achieving clinical, regulatory, and financial milestones.
- Lexicon will use the initial tranche to repay its existing loan facility with Oxford Finance.
The big picture
Lexicon Pharmaceuticals' $100 million loan facility from Hercules Capital provides non-dilutive capital, enhancing its financial flexibility to support upcoming regulatory and commercial milestones. This move aligns with broader trends in biotech financing, where companies seek to strengthen balance sheets without diluting equity. The deal underscores Hercules Capital's commitment to funding innovative therapies in the cardiometabolic space.
What we're watching
- Milestone Achievement
- Whether Lexicon can meet the clinical, regulatory, and financial milestones required to draw the second $20 million tranche.
- Debt Management
- How Lexicon will manage the floating interest rate and the potential extensions of the interest-only period.
- Pipeline Advancement
- The pace at which Lexicon advances its late-stage cardiometabolic programs with the additional financial flexibility.
Related topics